CTOs on the Move

Whole30

www.whole30.com

 
As featured in the New York Times bestselling book, The Whole30
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.whole30.com
  • 4001, South 700 East
    Salt Lake City, UT USA 84107
  • Phone: 321.209.1480

Executives

Name Title Contact Details

Similar Companies

Gilda'S Club

Gilda'S Club is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Southwell

With a reputation as an innovative provider of quality care, Southwell is a growing, not-for-profit health system serving 12 counties in South Central Georgia. Southwell offers more than 135 physicians with expertise in over 30 specialties. Southwell provides a wide-range of care, including signature services in surgery, oncology, cardiovascular care, women`s health, neurodiagnostics, geriatric psychiatric care, radiology and more. The Main Campus is Tift Regional Medical Center, a 181-bed regional referral hospital located in Tifton. Our Tifton West Campus houses various diagnostic services and the region`s largest multi-specialty clinic. Our Cook County campus is anchored by Southwell Medical, an acute care facility which includes state-of-the-art surgical services and a 12-bed geriatric psychiatric unit. The Cook campus also includes Southwell Health and Rehabilitation, a 95-bed skilled rehabilitation facility.

ABK Biomedical

ABK Biomedical Inc. combines a compelling clinical market need with innovative biomaterials invented by Drs. Bob Abraham, Daniel Boyd and Sharon Kehoe.

Catalyst Biosciences

Catalyst Biosciences is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in South San Francisco, CA. To find more information about Catalyst Biosciences, please visit www.catbio.com

Scynexis

SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. We are developing our lead product candidate, SCY-078, a novel antifungal in Phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.